Immunotherapy | Clinical

Immunotherapy and Targeted Therapy Triplet Active in Microsatellite Stable mCRC

January 27, 2021

The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity among patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild-type, according to findings from a phase 2 LCCC1632 study.

Practice Gaps for Immunotherapy Identified in Community Oncology Centers

December 14, 2020

Only 61% of patients completed therapy fully with checkpoint inhibition as planned, while treatment was delayed or discontinued in 22% due to immune-related adverse events, according to findings from a quality improvement research study conducted by the Association of Community Cancer Centers.

Many Oncologists Favor Consolidation Immunotherapy Following Chemoradiation for Stage III NSCLC

November 21, 2020

During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.

Novel Small Molecule +/- Pembrolizumab Induces Responses in Various Solid Tumors

November 17, 2020

The oral small molecule FLX475 demonstrated promise when administered either alone or in combination with the immune checkpoint inhibitor pembrolizumab in multiple solid tumors, according to findings from a phase 1/2 dose-escalation and expansion study.

TMB Use as Immunotherapy Biomarker Fraught by Challenges, But Still Shows Potential

November 07, 2020

Tumor mutational burden has been correlated with response to immunotherapy use in patients treated with immune checkpoint blockade. However, use of this biomarker has been challenged along the way with various criticisms of validity and routine use.

Immunotherapy Combinations Appear Efficacious in Long-Term Follow-up of Advanced RCC

October 30, 2020

In an interview with Targeted Oncology, Laurence Albiges, MD, PhD, discussed the updated findings for the combination of nivolumab and ipilimumab as treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma.

Investigators Attempt to Uncover Basis Behind Sexual Dysmorphic and Age-Related Responses to Immunotherapy

September 17, 2020

An analysis of patient samples from The Cancer Genome Atlas indicated a possible connection between tumor responses to immunotherapy and patient baseline characteristics after investigators discovered evidence of stronger immune selection by female and younger patients in early tumorigenesis.

JAVELIN Bladder 100 Trial Impresses, Ensures Patients Have Access to Second-Line Immunotherapy at Disease Progression

July 07, 2020

Results from the study, JAVELIN Bladder 100, demonstrated that in patients who have achieved stable disease or better after first-line platinum-based chemotherapy, maintenance avelumab significantly improved both progression-free survival and overall survival compared with best supportive care alone.